

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

CF

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 4 : <u>A61K 9/40, 9/22, 9/52</u>		A1	(11) International Publication Number: WO 85/04100 (43) International Publication Date: 26 September 1985 (26.09.85)
(21) International Application Number: PCT/US85/00300 (22) International Filing Date: 22 February 1985 (22.02.85)		(74) Agents: ROUTH, John, W. et al.; 685 Third Avenue, New York, NY 10017 (US).	
(31) Priority Application Number: 591,738 (32) Priority Date: 21 March 1984 (21.03.84) (33) Priority Country: US		(81) Designated States: AU, DK, FI, JP, KR. Published <i>With international search report.</i>	
(71) Applicant: AMERICAN HOME PRODUCTS CORPORATION [US/US]; 685 Third Avenue, New York, NY 10017 (US).			
(72) Inventors: KALIDINDI, Sanyasi, Raju ; 36B Arlington Square Apartments, 1148 Mulberry Lane, Greenville, NC 27834 (US). GIANNINI, Robert, Peter ; 508 Meadowbrook Road, East Norriton, PA 19401 (US). GASKILL, James, Lawrence ; Apartment M-307, Sunnyside and Avon Roads, Devon, PA 19333 (US). RUSSO, Emanuel, Joseph ; 8 Morris Circle, Wayne, PA 19087 (US).			

(54) Title: SUSTAINED RELEASE PHARMACEUTICAL CAPSULES

(57) Abstract

A gastrointestinal, pH-independent, sustained-release pharmaceutical unit dosage form comprising a non-compressed mixture of a therapeutic agent and from about 10 to about 60 percent by weight of a high molecular weight hydroxypropylmethylcellulose, and a method for production thereof in hard gelatin capsules.

-1-

**SUSTAINED RELEASE
PHARMACEUTICAL CAPSULES**

American Home Products Corporation, a Corporation organised and existing under the laws of the State of Delaware, United States of America of 685 Third Avenue, New York, New York 10017, United States of America.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GA	Gabon	MR	Mauritania
AU	Australia	GB	United Kingdom	MW	Malawi
BB	Barbados	HU	Hungary	NL	Netherlands
BE	Belgium	IT	Italy	NO	Norway
BG	Bulgaria	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali		
FR	France				

Background of the Invention

The convenience and advantages of administering a single dose of medication which provides prolonged or sustained-release as opposed to the administration of a number of single doses at regular intervals are indisputable. Conventionally, 5 sustained-release is achieved by controlling dissolution and/or diffusion of the medicament from the dosage form. Several carrier materials which are employed for this purpose include waxes, fatty materials, polymers, natural, synthetic and semi-synthetic gums, etc. Among the gums, hydroxypropylmethylcelluloses constitute an important class of materials because of their pH-independent effect as well 10 as their synthetic origin as opposed to the natural gums such as alginates, Karaya, Guar, Locust bean, etc.

The use of hydroxypropylmethylcelluloses as carrier bases in sustained-action tablets has been well-established. For example, Christensen et al. (U.S. Patent 3,065,143) teach sustained-release tablets which contain a hydroxypropylmethyl- 15 cellulose which, upon contact with gastric fluid, swells and forms a water-impermeable barrier on the tablet surface thereby providing sustained release by diffusion of drug through the barrier. It is clear from their teachings that the gum has to be pressed into a tablet for it to work as a sustained-action agent. Sheth et al. (U.S. Patent 4,167,558) disclose sustained-release tablets containing hydroxy- 20 propylmethylcellulose 60 HG. Again the dosage form is tablet and in addition there is a restriction on the density of the tablets to assure buoyancy and release the whole of the medicament in the stomach. Lowey et al. (U.S. Patent 3,870,790) disclose a solid, compressed buccal product containing low molecular weight hydroxypropylmethylcellulose which has been modified by humidification and air-drying. 25 Similarly, Schor (U.S. Patent 4,226,849) disclosed the invention of tablets, lozenges, suppositories and/or other compressed dosage forms, which have prolonged-release wherein the hydroxypropylmethylcellulose has been subjected to hydrolysis and oxidation to generate a desired minimum concentration of carbonyl and carboxyl groups. The hydroxypropylmethylcellulose used in these teachings are 30 of low molecular weight. In another patent (U.S. Patent 4,389,393) Schor et al. disclose the use of high molecular weight hydroxypropylmethylcelluloses in low concentrations for achieving sustained drug release action from compressed solid dosage forms. The hydroxypropylmethylcelluloses used by Schor et al. have a 35 molecular weight above 50,000, a methoxyl content of 16-24% and hydroxypropoxy content of 4-32%. Thus, Schor et al. (4,389,393) require that the material be compressed and it is clear from these teachings and those of Christensen et al.

- 3 -

(U.S. Patent 3,065,143), Sheth et al. (4,167,558), Lowey et al. (3,870,790) and Schor et al. (4,226,849 and 4,389,393) that compression is essential for the formation of a diffusion barrier layer on the surface of the oral dosage form to provide sustained action.

Sheth and Tossounian (U.S. Patent 4,126,672) showed that hydroxypropyl-methylcellulose provides sustained release in a buoyant capsule dosage form. However, because of the buoyancy constraints, the density of the capsules may have to be adjusted by the use of a fatty material so that the capsules float in the gastric fluid. It is clear from their teachings that floating is essential for their concept to work. Henderson et al. (U.S. Patent 3,427,378) disclose capsules for sustained-release of medicament wherein a gum such as sodium alginate is incorporated into the pharmaceutical formulation in an amount of from 70 to 99 percent by weight and preferably 85 to 98 percent and the capsules are, as a critical feature, completely filled.

Description of the Invention

This invention provides a unit dosage form for administration of a therapeutic agent, which does not require expensive compression and granulation processing characteristic of the prior art sustained-release tablets, or density control restraints characteristic of the prior art capsules, while providing substantially the same slow drug release heretofore obtained with compressed tablets. The unit dosage form of this invention provides sustained release of drug independent of gastrointestinal pH and is therefore equally effective both in the stomach and intestine. By "independent," it is not meant that no change in dissolution rate occurs with change of pH, but that any change is so insubstantial that drug delivery is not meaningfully altered.

In essence, it has been discovered that pharmaceutical compositions formulated with relatively high molecular weight hydroxypropylmethylcellulose (> 50,000) which heretofore have been employed in the production of compressed unit dosage forms such as tablets, buccal lozenges, suppositories, etc. may be used without compression in hard gelatin capsules without loss of the sustained release effect observed in compressed tablets. Although the pharmaceutical literature has well documented the necessity for compressing hydroxypropylmethylcellulose-containing drug formulations to provide an external surface barrier to drug release, or for control of the density of an encapsulated drug formulation compounded with hydroxypropylmethylcellulose to provide buoyancy and hold the capsule in the

- 4 -

stomach, applicants have found that neither of these preparative restrictions are necessary to provide a sustained release unit dosage capsule for administration. The formulations employed in this invention are not tailored to ensure buoyancy in gastric fluids and they are equally effective when administered in such manner as to be retained with a food bolus passing into the small intestine. No special attention or limitation as to internal porosity is required with the formulations of this invention.

Thus, in accordance with this invention, there is provided a gastrointestinal, pH-independent, sustained-release pharmaceutical unit dosage form comprising a hard gelatin capsule containing a pulverulent admixture of a therapeutically active medicament; from about 10 to about 60 percent by weight of at least one hydroxypropylmethylcellulose possessing a methoxy content of 15 to 24 weight percent, a hydroxypropoxyl content of 4 to 32 weight percent and a number average molecular weight of at least 50,000; and a pharmaceutically acceptable, nonpharmacologically functional adjuvant therefor.

The hydroxypropylmethylcelluloses employed in production of the sustained-release capsules are commercially available. In essence, any hydroxypropylmethylcellulose (HPMC) possessing the characteristics of Methocel® K4M, K15M and K100M are applicable, individually and as mixtures. Each of these hydrophilic materials have a methoxy content of about 16 to about 24 weight percent, a hydroxypropyl content of about 4 to about 32 weight percent and a number average molecular weight of at least 50,000. The proportion of hydroxypropylmethylcellulose to total capsule weight may vary from about 10 to about 60 percent to provide release rates of drug over a 6 to about 12 hour period. Although the release rates achieved with hard gelatin capsules containing drug formulations and hydroxypropylmethylcellulose in accordance with this invention will differ somewhat depending upon the specific drug being compounded, the sustained release effect is readily achieved. Modification of the release rate may be attained by altering the hydroxypropylmethylcellulose to drug ratio within the limits indicated above. Generally, an increased content of hydroxypropylmethylcellulose will prolong the release rate of a given drug as may be seen from the experimental data presented, infra. An optimum release rate is obtained when ~~less~~ total dissolution of the therapeutic agent at a substantially uniform rate is achieved over a period of from six to twelve hours and preferably in about eight hours.

Any therapeutic agent suitable for oral administration may be formulated in conformance with this disclosure and encapsulated to provide a sustained release

- 5 -

unit dosage capsule. Thus, tranquilizers, analgesics, antihypertensives and similar drugs may be readily formulated for use in sustained release capsule form.

In addition to the therapeutic agent and hydroxypropylmethylcellulose, other conventional additives such as fillers and binders (microcrystalline cellulose, lactose, dicalcium phosphate dihydrate, etc.); lubricants (magnesium stearate, stearic acid, etc.); glidants (colloidal silicon dioxide, talc, etc.); hydrophilic gums (methylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, sodium carboxymethylcellulose, etc.); disintegrants (starch, sodium starch glycolate, etc.); preservatives (methylparahydroxy benzoate, benzoic acid, etc.); antioxidants (ascorbic acid, sodium bisulfite, etc.) and colorants (certified dyes) may be employed in the formulations for filling hard gelatin capsules without materially changing the sustained release rate of medicament achieved with the indicated high molecular weight hydroxypropylmethylcellulose material.

The pharmaceutical compositions of this invention are prepared by blending an admixture of the ingredients and filling hard gelatin capsules therewith by hand or machine. Where the particulate size of any one component of the composition, or the mixture in its entirety, is of such size as to detract from the production of a homogeneous or near homogeneous blend for subsequent processing, or the desired performance of the finished dosage form (e.g. dissolution, stability, uniformity, weight variation, etc.), that component or the entire mixture may be milled to any desired size prior to a final blending and capsule filling.

The following examples illustrate several specific formulations for filling hard gelatin capsules to produce sustained release doses of the indicated therapeutic agents. For purposes of this illustration, the drugs used were:

Oxazepam 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one;
Ciramadol 1-cis-2-(α -dimethylamino-m-hydroxybenzyl)cyclohexanol;
Guanabenz (E)-[(2,6-dichlorobenzylidene)amino]guanidine; and
Lorazepam 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one.

- 6 -

Example 1Hydroxypropylmethylcellulose 10 percent

		<u>mg</u>
	Oxazepam USP	30.00
5	Hydroxypropylmethylcellulose 2208 USP	37.50
	Microcrystalline Cellulose NF	94.00
	Lactose USP Hydrous	206.75
	Colloidal Silicon Dioxide NF	3.75
	Magnesium Stearate NF	3.00
		<hr/>
10	<u>TOTAL</u>	375.00

Example 2Hydroxypropylmethylcellulose 20 percent

		<u>mg</u>
	Oxazepam USP	30.00
15	Hydroxypropylmethylcellulose 2208 USP	75.00
	Microcrystalline Cellulose NF	94.00
	Lactose USP Hydrous	169.25
	Colloidal Silicon Dioxide NF	3.75
	Magnesium Stearate NF	3.00
		<hr/>
20	<u>TOTAL</u>	375.00

Example 3Hydroxypropylmethylcellulose 30 percent

		<u>mg</u>
	Oxazepam USP	30.00
25	Hydroxypropylmethylcellulose 2208 USP	112.00
	Microcrystalline Cellulose NF	94.00
	Lactose USP Hydrous	131.75
	Colloidal Silicon Dioxide NF	3.75
	Magnesium Stearate NF	3.00
		<hr/>
30	<u>TOTAL</u>	374.50

- 7 -

Example 4Hydroxypropylmethylcellulose 25 percent

	<u>mg</u>
Ciramadol Hydrochloride	68.80
Hydroxypropylmethylcellulose 2208 USP	112.50
Microcrystalline Cellulose NF	110.26
Lactose USP Hydrous	152.27
Colloidal Silicon Dioxide NF	4.50
Magnesium Stearate NF	1.67
 <u>TOTAL</u>	 450.00

Example 5Hydroxypropylmethylcellulose 60 percent

	<u>mg</u>
Guanabenz Acetate	20.20
Hydroxypropylmethylcellulose 2208 USP	90.00
Lactose USP Hydrous	39.05
Magnesium Stearate NF	0.75
 <u>TOTAL</u>	 150.00

Example 6Hydroxypropylmethylcellulose 40 percent

	<u>mg</u>
Lorazepam	2.00
Hydroxypropylmethylcellulose 2208 USP	40.00
Microcrystalline Cellulose NF	30.00
Lactose USP Hydrous	27.50
Magnesium Stearate NF	0.50
 <u>TOTAL</u>	 100.00

- 8 -

In each of the preceding examples, all the ingredients were mixed together in a Twin-shell blender for 10 minutes, milled through a Fitz Mill®, and mixed again for 10 minutes in the same blender. The blend was then filled into hard gelatin capsules using a Zanasi LZ64 capsule-filling machine.

5 The above formulations provide sustained-release for 6-12 hours in vitro as shown in Table I. The dissolution rate study employed to obtain the data reported in Table I was performed in an apparatus conforming to that described as Apparatus 2 in U.S. Pharmacopeia XX page 959 (1980) by the method therein described, at 50 r.p.m. or 100 r.p.m. The dissolution medium was 500 ml 0.1N HCl
 10 for the first hour after which 500 ml phosphate buffer was added to afford a pH of 7.4, comparable to that found in the intestine. A spring coil was employed to sink the capsules and insure that they did not float.

15 Table I: Dissolution Data for Various Sustained-Action Capsules
 Containing Hydroxypropylmethylcellulose Carrier Base.
 (% Drug Dissolved as an Average of Six Capsules)

Formulation of

<u>Example No.</u>	<u>1 Hour</u>	<u>2 Hours</u>	<u>4 Hours</u>	<u>6 Hours</u>	<u>8 Hours</u>	<u>12 Hours</u>
1	20	57	90	97	-	-
2	26	56	79	86	88	94
20 3	15	36	55	69	79	92
4	37	60	82	95	100	-
5	28	47	68	84	93	94
6	20	32	50	67	82	94

25 To illustrate the comparable dissolution rates between compressed tablets and the capsules of this invention employing the same formulation, the following data was obtained with the appropriate formulations disclosed, supra, and with that of Example 7.

- 9 -

Example 7Hydroxypropylmethylcellulose 38.6 percent

Guanabenz Acetate	20.2 mg
Hydroxypropylmethylcellulose 2208, USP	61.7 mg
Magnesium stearate, NF	0.55 mg
Microcrystalline cellulose, NF	22.0 mg
Lactose, USP	45.6 mg
Sodium starch glycolate, NF	10.0 mg
TOTAL	160.0 mg

10 The tablets were conventionally prepared and the capsules were prepared by machine-filling as described, supra. The procedure followed in obtaining this dissolution rate data was the same as that disclosed, supra, except that the study employing guanabenz were run in all acid (0.1N HCl) without addition of buffer, and all samples were run at a paddle speed of 50 RPM.

15 Table II: Dissolution Data Comparing Tablets and Capsules Prepared With the Same Powder Blend or Granulation.
(% Dissolved as an Average of Six Capsules and Tablets)

20	Time (Hours)	Oxazepam with 20% HPMC 2208 USP		Guanabenz with 38.6% HPMC 2208 USP		Ciramadol with 25% HPMC 2208 USP	
		Tablets	Capsules	Tablets	Capsules	Tablets	Capsules
	1	12.5	13.5	35.0	37.5	26.5	37
	2	22.5	22.5	52.0	56.0	41.5	60
	4	33.0	32.0	77.0	80.0	57.5	82
25	6	40.0	39.0	93.0	92.0	75.0	95
	8	46.0	46.0	93.0	98.0	85.0	complete
	10	52.5	52.0	95.5	98.0	93.5	complete
	12	56.5	55.5	97.0	96.0	96.5	complete

- 10 -

To demonstrate that there is no property imparted to the capsules of this invention by the encapsulating machine, the data presented in Table III compares the dissolution rate of hand-filled capsules with those containing the same formulations when filled with a Zanasi LZ64 encapsulating machine. The 5 formulations employed were those shown in Examples 2 and 6.

Table III: Dissolution of Hand-Filled and Machine-Filled Capsules
(% Dissolved as an Average of Six Capsules)

Time (Hours)	<u>Oxazepam (Example 2)</u>		<u>Lorazepam (Example 6)</u>	
	<u>Hand filled</u>	<u>Machine filled</u>	<u>Hand filled</u>	<u>Machine filled</u>
10	17	26	24	20
	44	56	37	32
	68	79	55	50
	80	86	71	67
15	81	88	88	82
	84	94	99	94
	91	98	100	94

From these data, the preferred quantity of defined hydroxypropylmethylcellulose for general incorporation into pharmaceutical formulations for encapsulation can be seen to be from about 10 to about 50 weight percent. For the individual drugs herein exemplified the preferred quantity of defined hydroxypropylmethylcellulose is from about 15 to about 40 weight percent with oxazepam; about 20 to about 50 weight percent with lorazepam and from about 15 to about 50 weight percent with ciramadol.

25 Thus, the advantages of capsule dosage forms with no loss of sustained drug-release rate presently found in compressed tablets, clearly characterizes the benefits of this invention.

- 11 -

CLAIMS

1. A gastrointestinal pH independent sustained release pharmaceutical unit dosage form comprising a hard gelatin capsule containing a pulverulent admixture of a therapeutically active medicament; from about 10 to about 60 percent by weight of at least one hydroxypropylmethylcellulose possessing a methoxy content of 16 to 24 weight percent, a hydroxypropoxyl content of 4 to 32 weight percent and a number average molecular weight of at least 50,000; and a pharmaceutically acceptable, nonpharmacologically functional adjuvant therefor.

5 2. A pharmaceutical unit dosage form of Claim 1 in which said hydroxy-
10 propylmethylcellulose is present in an amount of from about 10 to about 50 percent by weight.

15 3. A sustained-release pharmaceutical composition in capsule form as claimed in Claim 1 for oral administration of oxazepam, which comprises a pharmaceutically effective amount of oxazepam admixed with a hydroxypropyl-methylcellulose wherein said hydroxypropylmethylcellulose has a methoxyl content of about 16-24 percent, a hydroxypropoxyl content of about 4-32 percent and an average number molecular weight above 50,000 and said hydroxypropylmethyl-cellulose represents between about 10 to about 60 weight percent of the contents of said capsule.

20 4. A pharmaceutical composition in capsule form as claimed in Claim 3 in which said hydroxypropylmethylcellulose represents between about 15 to about 40 percent of the contents of said capsule.

25 5. A sustained-release pharmaceutical composition in capsule form as claimed in Claim 1 for oral administration of lorazepam, which comprises a pharmaceutically effective amount of lorazepam admixed with a hydroxypropyl-methylcellulose wherein said hydroxypropylmethylcellulose has a methoxyl content of about 16-24 percent, a hydroxypropoxyl content of about 4-32 percent and an average number molecular weight above 50,000 and said hydroxypropylmethyl-cellulose represents between about 10 to about 60 weight percent of the contents of said capsule.

- 12 -

6. A pharmaceutical composition in capsule form as claimed in Claim 5 in which said hydroxypropylmethylcellulose represents between about 20 to about 50 percent of the contents of said capsule.

5 7. A sustained-release pharmaceutical composition in capsule form as claimed in Claim 1 for oral administration of ciramadol, which comprises a pharmaceutically effective amount of ciramadol admixed with a hydroxypropylmethylcellulose wherein said hydroxypropylmethylcellulose has a methoxyl content of about 16-24 percent, a hydroxypropoxyl content of about 4-32 percent and an average number molecular weight above 50,000 and said hydroxypropylmethylcellulose represents between about 10 to about 60 weight percent of the contents of said capsule.

10 8. A pharmaceutical composition in capsule form as claimed in Claim 7 in which said hydroxypropylmethylcellulose represents between about 15 to about 50 percent of the contents of said capsule.

15 9. A sustained-release pharmaceutical composition in capsule form as claimed in Claim 1 for oral administration of guanabenz, which comprises a pharmaceutically effective amount of guanabenz admixed with a hydroxypropylmethylcellulose wherein said hydroxypropylmethylcellulose has a methoxyl content of about 16-24 percent, a hydroxypropoxyl content of about 4-32 percent and an average number molecular weight above 50,000 and said hydroxypropylmethylcellulose represents between about 10 to about 60 weight percent of the contents of said capsule.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US35/003001

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ¹⁾

According to International Patent Classification (IPC) or to both National Classification and IPC

A61K 9/40, A61K 9/22, A61K 9/52

II. FIELDS SEARCHED

Minimum Documentation Searched ⁴⁾

Classification System	Classification Symbols
US	424/37, 19

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched ⁵⁾

III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴⁾

Category ⁶⁾	Citation of Document, ¹⁵⁾ with indication, where appropriate, of the relevant passages ¹⁷⁾	Relevant to Claim No. ¹⁸⁾
Y	US,A, 3,065,143 to Christenson, Published 20 Nov. 1962	1-9
Y	US,A, 3,870,790 to Lowey <u>et al.</u> , published 11 March 1975	1-9
X,Y	US,A, 4,126,672 to Sheth <u>et al.</u> , published 21 Nov. 1978	1-9
Y	US,A, 4,167,558 to Sheth <u>et al.</u> , published 11 Sept. 1979	1-9
X,Y	US,A, 4,173,626 to Dempski <u>et al.</u> , published 6 Nov. 1979	1-9
Y	US,A, 4,226,849 to Schor, published 7 Oct. 1980	1-9

* Special categories of cited documents: ¹⁵⁾

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATE

Date of the Actual Completion of the International Search ¹⁹⁾

5 May 1985

Date of Mailing of this International Search Report ¹⁹⁾

13 MAY 1985

International Searching Authority ²⁰⁾

IS/US

Signature of Authorized Officer ²⁰⁾